Accession | Title | Sample type | Organism(s) | Ch | Platform | Series | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|---|
Filter | TSV | Mark Dawson | Nov 08, 2021 | ||||||
GSM4912395 |
mll-af9 + kras g12d/+ (KF05)
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912480 |
MLL-AF9 baseline
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912481 |
Ptprca Disease mouse 1
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912482 |
PtprcaDisease mouse 2
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912483 |
NSG Disease mouse 4
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912484 |
NSG Disease mouse 6
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912485 |
MLL-AF9 baseline ATAC
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912548 |
mll-af9 (KF09)
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912549 |
mll-af9 + flt3 itd/itd (KF09)
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912550 |
mll-af9 + kras g12d/+ (KF09)
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912551 |
Pool 1 - MLL-AF9 KRAS M8 & MLL M2
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912552 |
Pool 2 - FLT3 M11 & COMBO 1-1-1 M17
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912553 |
Pool 3 - MLL M3 & FLT3 M12
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912554 |
Pool 4 - COMBO 1-1-1 M19 & COMBO 80-15-5 M22
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM4912555 |
Pool 5 - KRAS M10 & COMBO 80-15-5 M24
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM5643580 |
chemo baseline scRNAseq tech rep 1
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM5643581 |
chemo baseline scRNAseq tech rep 2
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM5643582 |
chemo disease endpoint scRNA-seq pool 1
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM5643583 |
chemo disease endpoint scRNA-seq pool 2
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 | |||
GSM5643584 |
chemo disease endpoint scRNA-seq pool 1 hashtag library
|
SRA | 1 |
|
Mark Dawson | Nov 08, 2021 |